Abstract
In the era of advancement of biotechnology and molecular biology, the structure, catalytic site specification, role in biochemical processes, and many diseases of an enzyme have been discovered. Enzymes are protein in nature and are formulated in the human body from amino acids. Each enzyme carries its specific functions in the body and has particular substrates to work with. The enzymes are present in the optimal amount in the body to carry out essential functions for life and health. Proteases or proteinases or peptidases are the largest family of proteolytic enzymes whose primary function is cleaving proteins into smaller fragments. Due to their structural and functional diversity, these enzymes carry out many functions, including intracellular protein formation or recycling, nutrient digestion, and immune system cascade formation. Proteases have been used for years commercially in leather industries, in beer industries to prevent agglomeration of proteins, and detergent formulations. Still, in recent years their therapeutic functions have been discovered and utilized in the pharmaceutical industry. They have been used in the curing, diagnosis, and replacement therapies, etc. Proteases with the development of microbiology and protein engineering have been hitting the market now quite frequently as drugs/therapeutic agents. The U.S. FDA (Food and Drug Administration) now has approved various therapies utilizing protease enzymes as a therapeutic entities, and many next-generation or completely new proteases are in clinical development. There are multiple proteases in the development stage of clinical and preclinical trials. The utilization of enzymes has not achieved 100 percent of its potential mainly due to two reasons: the first reason is the economical difficulties in obtaining pure and homogeneous enzymes leading to higher cost issues, and second the immunogenicity, fast degradation, and inactivation in the body by inhibitors and secretions and due to Physiological pH and temperature barriers. The present article attempts to introduce various therapeutic roles of these enzymes and methods to utilize them to the maximum of their potential in the medical/pharmaceutical field.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A et al (2005) Drotrecogin α(activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341
Aiuti A (2002) Advances in gene therapy for adenosine deaminase deficient SCID. Curr Opin Mol Therap. 4:515–522
Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25–40. https://doi.org/10.1007/s000180050497
Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamfi J, Baker RD (2005) Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr 146:189–193. https://doi.org/10.1016/j.jpeds.2004.09.003
Barett AJ (1994) Proteolytic enzymes: serine and cysteine peptidases. Methods Enzymol 244:1–15
Barett AJ (1995) Proteolytic enzymes: aspartic and metallopeptidases. Methods Enzymol 248:183
Bethune MT, Khosla C (2012) Oral enzyme therapy for celiac sprue. Methods Enzymol 502:241–271. https://doi.org/10.1016/B978-0-12-416039-2.00013-6
Boguslawski G, Shultz JL, Yehle CO (1983) Purification and characterization of an extracellular protease from Flavobacterium arborescens. Anal Biochem 132:41–49. https://doi.org/10.1016/0003-2697(83)90423-2
Bowman LJ, Anderson CD, Chapman WC (2010) Topical recombinant human thrombin in surgical haemostasis. Semin Thromb Hemostasis 36:477–484. https://doi.org/10.1055/s-0030-1255441
Braun JM, Schneider B, Beuth HJ (2005) Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS® in children with acute sinusitis in Germany. In Vivo 19:417–422
Cassileth B (1998) The alternative medicine handbook, 1st edn. W.W Norton, New York, USA
Chapman WC, Singla N, Genyk Y, McNeil JW, Renkens KL, Reynolds TC, Murphy A, Weaver FA (2007) A Phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical haemostasis. J Am Coll Surg 205:256–265. https://doi.org/10.1016/j.jamcollsurg.2007.03.020
Chung CH, Goldberg AL (1981) The product of the lon (capR) gene in Escherichia coli is the ATP dependent protease, protease La. Proc Natl Acad Sci USA 78:4931–4935. https://doi.org/10.1073/pnas.78.8.4931
ClinicalTrials.gov. National Library of Medicine (U.S.). (June 2005) The safety of four different dose levels of wobenzym in HIV-positive patients. Identifier: NCT00002311. https://clinicaltrials.gov/ct2/show/NCT00002311?term=NCT+0000231
ClinicalTrials.gov. National Library of Medicine (U.S.). (April 2007) Complementary Therapies for the reduction of side effects during chemotherapy for breast cancer. Identifier: NCT00160901. https://clinicaltrials.gov/ct2/show/NCT00160901?term=NCT+00160901&draw
ClinicalTrials.gov. National Library of Medicine (U.S.). (May 2010) Assessment of the safety and efficacy of DERMASTREAM™—ENZYSTREAM™ system for the treatment of chronic venous ulcers (ENZ-DER-002-IL). Identifier: NCT00485329 https://clinicaltrials.gov/ct2/show/NCT00485329?term=NCT00485329&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Nov 2010) Treatment of burns related contracture. Identifier: NCT01237964. https://clinicaltrials.gov/ct2/show/NCT01237964?term=NCT01237964&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Jun 2011) Effects of gluten digestion with ALV003 vs placebo. Identifier: NCT00859391. https://clinicaltrials.gov/ct2/show/NCT00859391?term=NCT00859391&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (September 24, 2012), Bromelain and Cardiovascular Risk Factors in Diabetes (BRCARDIO) Identifier:NCT01524159. https://clinicaltrials.gov/ct2/show/NCT01524159
ClinicalTrials.gov. National Library of Medicine (U.S.). (Nov 2012) Santyl vs sharp debridement of diabetic wounds. Identifier: NCT01056198
ClinicalTrials.gov. National Library of Medicine (U.S.). (Aug 2012) To evaluate the safety and efficacy of ALV003 to treat celiac disease. Identifier: NCT00959114. https://clinicaltrials.gov/ct2/show/NCT00959114?term=NCT00959114&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.) (March 2013) Chemomechanical caries removal using papain gel (CMCR09). Identifier: NCT01811420. https://clinicaltrials.gov/ct2/show/NCT01811420?term=NCT01811420&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (July 2014) Using santyl on diabetic foot ulcer. Identifier: NCT01408277. https://clinicaltrials.gov/ct2/show/NCT01408277?term=NCT+01408277&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Nov 2014). Intravenous administration of microplasmin for treatment of acute ischemic stroke. Identifier: NCT00123305. https://clinicaltrials.gov/ct2/show/NCT00123305?term=NCT00123305&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 2014) Evaluation of limb-girdle muscular dystrophy. Identifier: NCT00893334. https://clinicaltrials.gov/ct2/results?cond=&term=NCT00893334&cntry=&state=&city=&dist=
ClinicalTrials.gov. National Library of Medicine (U.S.). (January 19, 2015) Bromelain, Comosain as a new drug for treating and preventing various types of cancer in the humans. Identifier: NCT02340845. https://clinicaltrials.gov/ct2/show/NCT02340845
ClinicalTrials.gov. National Library of Medicine (U.S.). (April 2015) Effective treatments for jellyfish stings. Identifier: NCT02015195. https://clinicaltrials.gov/ct2/show/NCT02015195?term=NCT+02015195&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (July 2015) Efficacy evaluation of the (Serodase 5 mg tablet) in the treatment of inflammation after third molar surgery. Identifier: NCT02493179. https://clinicaltrials.gov/ct2/show/NCT02493179?term=NCT+02493179&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.) (March 2016) A comparative study of Papacarie® and the conventional method for dental caries treatment. Identifier: NCT01641861. https://clinicaltrials.gov/ct2/show/NCT01641861?term=NCT01641861&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Feb 2017) Double blind study to evaluate the Efficacy in reducing surface area of subcutaneous benign lipoma. Identifier: NCT02249052. https://clinicaltrials.gov/ct2/show/NCT02249052?term=NCT+02249052&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Aug 2017) A phase 1 study of prometic plasminogen (human) in adults and children with hypoplasminogenemia. Identifier: NCT02312180. https://clinicaltrials.gov/ct2/show/NCT02312180?term=NCT02312180&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 2018) Phlogenzym® in patients with acute thrombophlebitis—efficacy and tolerance. Identifier: NCT03470337. https://clinicaltrials.gov/ct2/show/NCT03470337?term=NCT+03470337
ClinicalTrials.gov. National Library of Medicine (U.S.) (May 2018) Studying impacts on malabsorption with liprotamase in cystic fibrosis. Identifier: NCT02734810. https://clinicaltrials.gov/ct2/show/NCT02734810?term=NCT02734810&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Jun 2018) The study to reevaluate the safety and efficacy of human urinary kallikrein. Identifier: NCT02562183. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02562183&cntry=&state=&city=&dis
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 2019) A study to evaluate the efficacy and safety of NexoBrid in children with thermal burns compared the standard of care. Identifier: NCT02278718. https://clinicaltrials.gov/ct2/show/NCT02278718?term=NCT02278718&draw=2&rank
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 2019). Bromelain, a compound prepared with Ananas comocus extract and honey, for acute cough. Identifier: NCT01356693. https://clinicaltrials.gov/ct2/show/NCT01356693?term=NCT01356693&draw=2&rank
ClinicalTrials.gov. National Library of Medicine (U.S.). (January 31, 2019) Microbiological assessment after chemo-mechanical caries removal using papain-based enzyme versus conventional rotary tools in occlusal carious lesions. Identifier: NCT03408626. https://clinicaltrials.gov/ct2/show/NCT03408626?term=NCT03408626&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Sept 2019) Collagenase injection in recurrent dupuytren disease. Identifier: NCT03406338. https://clinicaltrials.gov/ct2/show/NCT03406338?term=NCT+03406338&draw=2&rank=1
ClinicalTrials.gov. National Library of Medicine (U.S.). (Sept 2019) The effect of human urinary kallikrein on corticospinal tract injury in acute ischemia stroke patients. https://clinicaltrials.gov/ct2/show/NCT04102956
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 9, 2020) Injection of bromelain and acetylcysteine in combination into recurrent mucinous tumour or Pseudomyxoma peritonei. Identifier: NCT03976973. https://clinicaltrials.gov/ct2/show/NCT03976973
ClinicalTrials.gov. National Library of Medicine (U.S.). (March 15 2020) Trial of supplement of quercetin, bromelain & papain on reducing severity of radiation-induced prostatitis (PROSTA-Q). Identifier: NCT04252625. https://clinicaltrials.gov/ct2/show/NCT04252625
ClinicalTrials.gov. National Library of Medicine (U.S.) (March 17 2020). Impacts of a combined berry extract supplement on vascular function and oxygen utility capacity in young adults. Identifier: NCT04312022. https://clinicaltrials.gov/ct2/show/NCT04312022?term=Bromelain%2B+Berry+extract&draw
Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions. Stephen Francis Olmstead, Reno, NV (US). US 2011/0177048 A1 Jul. 21, 2011. https://patents.google.com/patent/US20110177048A1/en?oq=US+20110177048+A1
Compositions and methods comprising serratia peptidase for inhibition of bacterial vaginosis, bacterial vaginitin or fungal vaginitis. Stephen Francis Olmstead, Reno, NV (US). US9737591B2 Aug 22, 2017. https://patents.google.com/patent/US9737591B2/en?oq=US+9737591+B2
Culhane S, George C, Pearo B, Spoede E (2013) Malnutrition in cystic fibrosis: a review. Nutr Clin Pract 28(6):676–683. https://doi.org/10.1177/0884533613507086
Daniele C, Saverio T, Ovidio B, Laurent RC, Maria VP, Rita D, Giovanna V, Claudia S (2012) Expanding targets for a metabolic therapy of cancer: l-asparaginase. Recent Pat Anticancer Drug Discov 7(1):4–13. https://doi.org/10.2174/157489212798358001
De Duve C (1966a) The significance of lysosome in pathology and medicine. Proc Inst Med Chic 266:73–76
De Duve C (1966b) The significance of lysosome in pathology and medicine. Proc Inst Med Chic 26:73–76
De Marco AC, Dick AJ (1978) Aminopeptidase I activities in several microorganisms. Can J Biochem 56:66–71. https://doi.org/10.1139/o78-010
Dellinger RP (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60. https://doi.org/10.1007/s00134-007-0934-2
Dental gel composition of papain for the atraumatic treatment of caries and method of preparing same. BRIX USA, LLC, Newark , DE (US). US 10, 137, 178 B2 Nov. 27, 2018. https://patents.google.com/patent/US10137178B2/en?oq=US+10%2c137%2c178+B2
Di Cera E (2007) Thrombin as procoagulant and anticoagulant. J Thromb Haemostasis 5:196–202. https://doi.org/10.1111/j.1538-7836.2007.02485
Di Cera E (2008) Thrombin. Mol Aspects Med 29:203–254. https://doi.org/10.1016/j.mam.2008.01.001
Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM (2004) Prophylactic urokinase in the management of long-term venous access devices in children: a Children’s Oncology Group study. J Clin Oncol 22:2718–2723. https://doi.org/10.3324/haematol.2011.050492
Esmon CT (2006) Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemostasis 32:49–60. https://doi.org/10.1055/s-2006-939554
Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Kurosawa DJ, Kurosawa S (1996) Inflammation, sepsis, and coagulation. Haematologica 84:254–259. https://doi.org/10.3324/%25
Felix F, Brouillet N (1966) Purification and properties of two peptidases from brewer’s yeast. Biochim Biophys Acta 122:127–144
Godfray T, West S (1996) Industrial enzymology, 2nd edn. Macmillan, New York
Gottesman S, Maurizi MR (1992) Regulation by proteolysis: energy-dependent proteases and their targets. Microbiol Rev 56:592–621
Hartley BS (1960) Proteolytic enzymes. Annu Rev Biochem 29:45–72. https://doi.org/10.1146/annurev.bi.29.070160.000401
Howard EL, Becker KC, Rusconi CP, Becker RC (2007) Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 27:722–727. https://doi.org/10.1161/01.ATV.0000259363.91070
Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919 (PMID: 7199524)
https://www.clinicaltrialsarena.com/projects/xiaflexdupuytens/. Accessed 5 May 2020
https://www.hrsa.gov/sites/default/files/opa/programrequirements/orphandrugexclusion-back/orphandruglist072016.pdf. Accessed 5 May 2020
https://www.webmd.com/men/peyronies-disease#1. Accessed 5 May 2020
Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I et al (2001) Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182–188. https://doi.org/10.1056/NEJM200101183440304
Kalisz MH (1988) Microbial proteinases. Adv Biochem Eng Biotechnol 36:17–55
Kisiel W (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by α-thrombin. J Clin Invest 64:761–769. https://doi.org/10.1172/JCI109521
Klasen HJ (2000) A review on the nonoperative removal of necrotic tissue from burn wounds. Burns 26:207–222. https://doi.org/10.1016/s0305-4179(99)00117-5
Kumar S (2018) The emerging role of serratiopeptidase in oral surgery: literature update. Asian J Pharm Clin Res 11(3):19–23. https://doi.org/10.22159/ajpcr.2018.v11i3.23471
Kush A, Thakur R, Patil SD, Paul ST, Kakanur M (2015) Evaluation of antimicrobial action of Carie Care™ and Papacarie Duo™ on Aggregatibacter actinomycetemcomitans a major periodontal pathogen using polymerase chain reaction. Contemp Clin Dent 6(4):534–538. https://doi.org/10.4103/0976-237X.169860
Labbe JP, Rebegrotte P, Turpine M (1974) Extracellular leucine aminopeptidase (EC 3.4.1.1) of Aspergillus oryzae (IP 410): leucine aminopeptidase 2 fraction. C R Acad Sci (Paris) 278D:2699
Lippi G, Mattiuzzi C, Favaloro EJ (2013) Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 39(1):48–58. https://doi.org/10.1055/s-0032-1328935
Littlewood JM, Wolfe SP, Conway SP (2006) Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 41:35–49. https://doi.org/10.1002/ppul.20286
Mahajan RT, Badgujar SB (2010) Biological aspects of proteolytic enzymes: a review. J Pharm Res 3(9):2048–2068
Matsumoto SFB, Motta LJ, Alfaya TA, Guedes CC, Fernandes Santos KP, Bussadori SK (2013) Assessment of chemomechanical removal of carious lesions using Papacarie Duo™: randomized longitudinal clinical trial. Indian J Dent Res 24(4):488–492. https://doi.org/10.4103/0970-9290.118393
Medved L, Nieuwenhuizen W (2003) Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemostasis 89:409–419 (PMID: 12624622)
Methods for reducing calcium deposits. Elgan A. Davis, 71.03 Marconi St., Huntington Park, Calif. 90255. US 4,250,167 Feb. 10, 1981. https://patents.google.com/patent/US4250167A/en?oq=US+4250167
Michel V (2003a) The enzyme as drug: application of enzymes as pharmaceuticals. Curr Opin Biotechnol 14:444–450. https://doi.org/10.1016/S0958-1669(03)00092-2
Monahan PE, Di Paola J (2010) Recombinant Factor IX for clinical and research use. Semin Thromb Hemostasis 36:498–509. https://doi.org/10.1055/s-0030-1255444
Mosnier LO, Bouma BN (2006) Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 26:2445–2453. https://doi.org/10.1161/01.ATV.0000244680.14653.9aArteriosclerosis
Nilsson G, Hojgard S, Berntorp E (2010) Treatment of the critically ill patient with protein C: is it worth the cost? Thromb Res 125:494–500. https://doi.org/10.1016/j.thromres.2009.09.008
Okada Y, Nagase H, Harris ED (1986) A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 261:14245–14255
Otín CL, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283(45):30433–30437
Papaine containing pharmaceutical formulation resp its use. Cristiano Alberto Ribeiro Santana, Sao Paulo (BR). US 2004/0146494 A1 Jul. 29, 2004. https://patents.google.com/patent/US20040146494A1/en?oq=US+2004%2f0146494+A1
Pharmaceutical compositions for aiding human digestion. Mohammad R. Ahmad, Glenview; Oscar A. Barke, Skokie, both of Ill. US5112611A May 12, 1992. https://patents.google.com/patent/US5112611A/en?oq=5%2c112%2c611
Proteolytic enzyme formulations. Jon Barron, Chatsworth, CA (US). Sep. 15, 2009 US 2010/0135919 A1. https://patents.google.com/patent/US20100135919
Puente XS, Sanchez LM, Gutierrez-Fernandez A, Velasco G, Lopez OC (2005) A genomic view of the complexity of mammalian proteolytic systems. Biochem Soc Trans 33:331–334. https://doi.org/10.1042/BST0330331
Rachel AE, Sanjay P, Ahuja A, Yousuf M (2016) l-Asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 7(2):62–71. https://doi.org/10.4103/0976-500X.184769
Ramundo J, Gray M (2008) Enzymatic wound debridement. J Wound Ostomy Continence Nurs 35:273–280. https://doi.org/10.1097/01.WON.0000319125.21854.78
Rao MB, Tanksale AM, Ghatge MS, Deshpande VV (1998) Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev 62(3):597–635
Rawlings ND, Barrett AJ (1993) Evolutionary families of peptidases. Biochem J 290:205–218. https://doi.org/10.1042/bj2900205
Rijken DC, Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemostasis 7:4–13. https://doi.org/10.1111/j.1538-7836.2008.03220
Roberts JW, Roberts CW, Mount DW (1977) Inactivation and proteolytic cleavage of phage repressor in vitro in an ATP-dependent reaction. Proc Natl Acad Sci USA 74:2283–2287. https://doi.org/10.1073/pnas.74.6.2283
Rodriguez D, Morrison CJ, Overall CM (2010) Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 1803:39–54. https://doi.org/10.1016/j.bbamcr.2009.09.015
Sabu A (2003) Sources, properties and applications of microbial therapeutic enzymes. IJBT 2:334–341
Semba CP, Sugimoto K, Razavi MK (2001) Alteplase and tenecteplase: applications in the peripheral circulation. Tech Vasc Interv Radiol 4:99–106. https://doi.org/10.1016/s1089-2516(01)90003-4
Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C (2002) Structural basis for gluten intolerance in celiac Sprue. Science 297:2275–2278. https://doi.org/10.1126/science.1074129
Shannon JD, Baramova EN, Bjarnason JB, Fox JW (1989) Amino acid sequence of a Crotalus atrox venom metalloprotease which cleaves type IV collagen and gelatine. J Biol Chem 264:11575–11583
Shin D, Shah T, Sadeghi-Nejad H (2018) Xiaflex for treatment of Peyronie’s disease. Eur Urol Focus 4(3):302–303. https://doi.org/10.1016/j.euf.2018.08.021
Sielecki AR, Fujinaga M, Read RJ, James MNG (1991) Refined structure of porcine pepsinogen at 1.8A resolution. J Mol Biol 219:671–692. https://doi.org/10.1016/0022-2836(91)90664-R
Smeekens SP (1993) Processing of protein precursors by a novel family of subtilisin-related mammalian endoproteases. Bio/Technology 11:182–186
Stafford CT (1990) The clinician’s view of sinusitis. Otolaryngol Head Neck Surg 103:870–874. https://doi.org/10.1177/01945998901030S506
Stafford DW (2003) The vitamin K cycle. J Thromb Haemostasis 3:1873–1878. https://doi.org/10.1111/j.1538-7836.2005.01419
Torchilin VP (1967) Immmobilized as drugs. Adv Drug Deliv Rev 1:41–86. https://doi.org/10.1016/0169-409X(87)90068-8
Townley WA, Baker R, Sheppard N, Grobbelaar AO (2006) Dupuytren’s contracture unfolded. BMJ 332:397–400. https://doi.org/10.1136/bmj.332.7538.397
Treatment of eczma with compositions containing bromelain. Merry Richon, Washington, DC (US). US 2018/0036392 Feb 8, 2018. A1. https://patents.google.com/patent/US20180036392A1/en?oq=US+2018%2f0036392+A1
Treatment of rosacea with compositions containing bromelain. Merry Richon, Washington, DC (US) Feb. 8, 2018. US 2018/0036390 A1. https://patents.google.com/patent/US20180036390A1/en?oq=+US+20180036390+A1%2c+++
Treatment of rosacea with compositions containing bromelain. Merry Richon, Washington, DC (US). Feb 20, 2020. US 10, 568, 944B2. https://patents.google.com/patent/US10568944B2/en?oq=US+10568944B2
Topical therapeutic compositions containing bromielan. Merry Richon, Washington, DC (US) US 2015/0238576A1 . https://patents.google.com/patent/US20150238576A1/en?oq=US+2015023857
Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing processes. Rainer Maurer, Berlin (DE); Klaus Eschmann, Kleinblittersdorf (DE). US 7,731,958 B2 Jun. 8, 2010. https://patents.google.com/patent/US7731958B2/en?oq=US+7731958B2
Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeiting JA, Van der Ploeg AT (2001) Enzyme therapy for Pompe disease with recombinant human a-glucosidase from rabbit milk. J Inherit Metab Dis 24:266–274. https://doi.org/10.1023/a:1010383421286
Van Melderen L, Thi M, Leechi P, Gottesman S, Couturier M, Maurizi ML (1996) ATP-dependent degradation of Ccd A by Lon protease. J Biol Chem 271:27730–27738. https://doi.org/10.1074/jbc.271.44.27730
Varma R, Haller JA, Kaiser PK (2015) Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion: results of the microplasmin for intravitreous injection-traction release without surgical treatment (MIVI-TRUST) trials. JAMA Ophthalmol 133(9):997–1004. https://doi.org/10.1001/jamaophthalmol.2015.1746
Yamasaki H, Tsuji H, Saeki K (1967) Anti-inflammatory action of a protease, TSP, produced by Serratia. Nihon Yakurigaku Zasshi 63(4):302–314 (in Japanese)
Acknowledgements
The authors thank to MM College of Pharmacy Maharishi Markandeshwar (Deemed to be University) Mullana Ambala, India for provide facilities.
Funding
No funding was received by the authors for preparation of this article.
Author information
Authors and Affiliations
Contributions
Ravi Shankar wrote the initial draft and Dr. Manish Kumar and Dr. Prabhat Kumar Upadhyay edited the manuscript. Both authors finalized the manuscript together and take responsibility for the content.
Corresponding author
Ethics declarations
Conflict of interest
There is no conflicts of interest of authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shankar, R., Upadhyay, P.K. & Kumar, M. Protease Enzymes: Highlights on Potential of Proteases as Therapeutics Agents. Int J Pept Res Ther 27, 1281–1296 (2021). https://doi.org/10.1007/s10989-021-10167-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-021-10167-2